ClinicalTrials.gg
Not yet recruitingNCT06633718Updated Oct 9, 2024

Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI

A Phase 3 interventional study of Meropenem and Pralurbactam and Saline in Intra-abdominal Infections, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-09.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
786
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Intraabdominal Infections with a site in China — 6 open to participants now, 6 under way, 1 of them phase 3. Intraabdominal Infections · China.

Planned enrollment
Largest of 17
786 · median 268
Started
2024
with 2 others
Phase 3
5 of 22
1 open now
Registered
17th of 22
by date

Among the 22 studies in Intraabdominal Infections with a site in China, this one has the largest planned enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2024, is one of 5 in phase 3, and was the 17th registered.

Intraabdominal Infections

129 studies on the registry are indexed under Intraabdominal Infections; 15 are open to participants now.

Browse Intraabdominal Infections studies →

Open to participants now

6 of the 22 studies in Intraabdominal Infections with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 10 Intraabdominal Infections studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Intraabdominal Infections with a site in China, or all of them as a file.
02

Study summary

This is a Phase 3, randomized, double-blind, multicenter, positive control study to assess the efficacy, safety, and pharmacokinetics of Meropenem and Pralurbactam compared with Ceftazidime-avibactam in combination with Metronidazole in the treatment of adult complicated intra-abdominal infections (cIAI).

Read the detailed description

This is a Phase 3, randomized, double-blind, multicenter, positive control study to assess the efficacy, safety, and pharmacokinetics of Meropenem and Pralurbactam compared with Ceftazidime-avibactam in combination with Metronidazole in the treatment of adult complicated intra-abdominal infections (cIAI). Treatment duration for each cohort was 7 to 14 days.

03

Conditions studied

  • Intra-abdominal Infections
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants ≥18 and ≤75 years of age.
  • Diagnosed or highly suspected cIAI.
  • Evidence of a systemic inflammatory response with at least one of the following:a. Fever ( temperature ≥ 38°C); b. hypotension (systolic blood pressure \< 90 mmhg); c. abdominal pain; d. nausea and/or vomiting; e. physical examination found abdominal mass; f. mental state change; g. other circumstances.
  • Female subjects must meet the following conditions: a. menopause for at least 1 year, or b. Sterilization has been performed, or C. Those who are fertile must meet the following conditions at the same time: the random pre-blood/urine pregnancy test is negative, effective measures are taken during the study period and within 30 days after the last application of experimental drugs, and eggs are not donated, and they are not breastfeeding.
  • Male subjects are willing to take effective contraceptive measures and not donate sperm during the study period and within 30 days after the last application of experimental drugs.
  • Understand and abide by the research procedures and methods, voluntarily participate in this research, and sign an form .

Exclusion criteria

Exclusion Criteria:

  • Allergic to any carbapenem, cephalosporin, penicillin, metronidazole disodium phosphate, other beta-lactam drugs or other beta-lactamase inhibitors and their auxiliary materials.
  • Non-complicated abdominal infection (infection is limited to abdominal organs), such as simple appendicitis and simple cholecystitis.
  • Abdominal wall infection or abscess (infection has not spread into abdominal cavity).
  • The rate in the screening period is ≤50mL/min.
  • The estimated survival time is less than 4 weeks.
  • Those who have a history of drug abuse or drug abuse within 6 months before screening.
  • Those who participated in other clinical trials within 28 days before randomization and used any test drugs or medical devices.
  • Any physiological or psychological disease or condition that may increase the risk of the experiment, affect the compliance of the subject with the protocol or affect the completion of the experiment as judged by the researcher.
  • Subjects are directly related persons who participated in this research.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
786 participants (estimated)

Study arms

  • Experimental
    Meropenem and Pralurbactam

    Meropenem and Pralurbactam (120min infusion)

    Drug: Meropenem and Pralurbactam · Drug: Saline

  • Active comparator
    Ceftazidime-avibactam

    Ceftazidime-avibactam (120min infusion) 、 Metronidazole(60min infusion)

    Drug: Ceftazidime-avibactam · Drug: Metronidazole

Interventions

  • DrugMeropenem and Pralurbactam

    Drug pages: Meropenem · Pralurbactam

    3g,q8h,120min infusion

  • DrugSaline

    100mL,q8h,60min infusion

  • DrugCeftazidime-avibactam

    2.5g,q8h,120min infusion

  • 0.915g,q8h,60min infusion

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Clinical Response of "Cure" at the Test of Cure (TOC) Visit

    Percentage of Participants With a Clinical Response of "Cure" at the Test of Cure (TOC) Visit

    Time frame: Up to approximately 28 days

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2024; primary completion for May 2027, 30 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2024
First posted
Oct 9, 2024
StartEst.
Oct 31, 2024
Primary completionEst.
May 30, 2027
CompletionEst.
May 30, 2027
Last update
Oct 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06633718
Responsible party
Sponsor
First posted
Oct 9, 2024
Start date
Oct 31, 2024 (estimated)
Primary completion
May 30, 2027 (estimated)
Completion
May 30, 2027 (estimated)
Last update
Oct 9, 2024

Study contacts

Yunsong Yu, Professor
Contact
yvys119@zju.edu.cn
+86-0571-85893267
Yuanyu Wang, Professor
Contact
Lywyy1979@126.com
+86-0571-85893889
Yunfei Ju, MM
study chair · Qilu Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Meropenem · Pralurbactam

Start the discussion